Int Neurourol J > Volume 22(2); 2018 > Article |
|
OAB subgroup | No. (%) | USS (score 0–4) | P-value | OABSS (score 0–15) | P-value | IPSS-S (score 0–15) | P-value |
---|---|---|---|---|---|---|---|
HSB | 31 (9.5) | 0.32 ± 0.48 | < 0.001a) | 3.16 ± 1.00 | 0.002a) | 4.61 ± 2.19 | 0.030a) |
OAB-dry | 74 (22.8) | 2.57 ± 0.53 | < 0.001b) | 5.31 ± 2.26 | < 0.001b) | 6.32 ± 2.74 | < 0.001b) |
OAB-wet | 220 (67.7) | 4.00 ± 0.07 | < 0.001c) | 9.44 ± 3.10 | < 0.001c) | 8.75 ± 3.19 | < 0.001c) |
Values are presented as mean±standard deviation unless otherwise indicated. The P-value is determined with 1-way analysis of variance by linear contrast.
USS, Urgency Severity Scale; OABSS, Overactive Bladder Symptom Score; IPSS-S, International Prostate Symptom Score–Storage Subscore; OAB, overactive bladder; HSB, hypersensitive bladder.
OAB subgroup | USS (score 0–4) | OABSS (score 0–15) | IPSS-S (score 0–15) |
---|---|---|---|
Rho (ρ) | 0.983 | 0.651 | 0.428 |
P-value | < 0.001 | < 0.001 | < 0.001 |
Variable |
HSB |
OAB-dry |
OAB-wet |
|||
---|---|---|---|---|---|---|
AUC (95% CI) | P-value | AUC (95% CI) | P-value | AUC (95% CI) | P-value | |
USS | 1.000 (0.989–1.000) | < 0.001a) | 0.953 (0.924–0.973) | < 0.001a) | 0.994 (0.979–0.999) | < 0.001a) |
OABSS | 0.935 (0.902–0.959) | < 0.001b) | 0.842 (0.797–0.880) | < 0.001b) | 0.888 (0.849–0.920) | < 0.001b) |
IPSS-S | 0.815 (0.769 –0.856) | < 0.001c) | 0.712 (0.659 –0.760) | < 0.001c) | 0.751 (0.700–0.797) | < 0.001c) |
The P-value was determined with the comparisons of the areas under ROC curve for each scoring systems in each OAB subgroup.
AUC, area under receiver operating characteristic curve; OAB, overactive bladder; HSB, hypersensitive bladder; CI, confidence interval; USS, Urgency Severity Scale; OABSS, Overactive Bladder Symptom Score; IPSS-S, International Prostate Symptom Score–Storage Subscore.
Rho (ρ) is the Spearman correlation coefficient. The P-value was determined by a subsequent significance test.
OAB, overactive bladder; USS, Urgency Severity Scale; OABSS, Overactive Bladder Symptom Score; IPSS-S, International Prostate Symptom Score–Storage Subscore; UUI, urgency urinary incontinence.
Variable |
USS |
||||
---|---|---|---|---|---|
0 (n = 21) | 1 (n = 10) | 2 (n = 33) | 3 (n = 41) | 4 (n = 220) | |
OABSS | |||||
Total | 3.24 ± 0.83 | 2.90 ± 1.20 | 3.97 ± 1.65 | 6.29 ± 2.05* | 9.40 ± 3.07* |
Frequency | 0.62 ± 0.67 | 0.30 ± 0.68 | 0.94 ± 0.83 | 0.90 ± 0.74 | 0.76 ± 0.76 |
Nocturia | 2.57 ± 0.75 | 2.40 ± 0.70 | 2.61 ± 0.66 | 2.63 ± 0.54 | 2.68 ± 0.58 |
Urgency | 0 | 0.30 ± 0.48 | 0.39 ± 1.20 | 2.27 ± 1.58* | 2.98 ± 1.47* |
UUI | 0.05 ± 0.05 | 0 | 0.03 ± 0.17 | 0.59 ± 0.89* | 3.02 ± 1.43* |
IPSS | |||||
Total | 5.9 ± 4.7 | 4.2 ± 2.66 | 5.88 ± 2.36 | 6.88 ± 2.59* | 8.68 ± 3.24* |
Frequency | 1.14 ± 1.91 | 0.9 ± 1.60 | 2.55 ± 2.17 | 2.56 ± 2.03 | 2.25 ± 2.07 |
Nocturia | 3.43 ± 1.54 | 2.9 ± 1.37 | 3.21 ± 1.39 | 3.17 ± 1.14 | 3.47 ± 1.26 |
Urgency | 0.05 ± 0.22 | 0.10 ± 0.32 | 0.06 ± 0.24 | 1.17 ± 1.63* | 3.00 ± 1.66* |